UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 13, 2024, Evoke Pharma, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
|
|
Exhibit No. |
|
Description |
99.1 |
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
EVOKE PHARMA, INC. |
|
|
|
|
Date: |
August 13, 2024 |
By: |
/s/ Matthew J. D'Onofrio |
|
|
|
Name: Matthew J. D'Onofrio |
Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results
GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million
Achieved record-high prescription fills during Q2
75% year-over-year prescription fill increase; 32% growth compared to Q1 2024
Two abstracts submitted and accepted by the American College of Gastroenterology (ACG) focusing on use of GIMOTI in patients on GLP-1 analogs
SOLANA BEACH, Calif., August 13, 2024 (GLOBE NEWSWIRE) – Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the second quarter ended June 30, 2024, and recent corporate developments.
Matt D’Onofrio, CEO of Evoke Pharma, commented, "Exiting the second quarter of 2024 with nearly 50% growth in revenue from the previous quarter is a testament to the effectiveness of our commercial strategy. This quarter, we made history by hitting record-high prescription fills while witnessing increases in all other key sales metrics."
“We are continuing to see growth in all phases of our business with increases in HCPs prescribing, patients taking GIMOTI, improvements in covered prescriptions with each showing our best performance in quarter over quarter growth in Q2. As of June 30, 2024, GIMOTI has over 2,000 cumulative prescribers. Additionally, our partnership with ASPN Pharmacies continues to yield strong results, notably in the conversion of prescriptions to fills,” Mr. D’Onofrio added.
Chris Quesenberry, Chief Commercial Officer for GIMOTI, stated, “Eversana’s aligned goal with Evoke is to improve the lives of patients suffering from diabetic gastroparesis by improving access to GIMOTI and offering it as in important alternative to current oral options. Sixty-five percent of patients are dissatisfied with current therapies for their gastroparesis, which is unacceptable. We will continue to challenge the narrative that “patients are doing fine,” taking our message to providers and patients alike. Our strategies to grow our prescriber and patient base are working, as the GIMOTI clinical data and their personal experience on treatment is resonating with patients and providers. Our current and planned strategic initiatives are poised to support continued momentum as we have only scratched the surface of the total opportunity thus far.”
Second Quarter 2024 Developments and Recent Highlights:
Strong Commercial Progress with GIMOTI
Unveiled Further Benefits of GIMOTI at Medical Meetings and Webinars
Leadership Appointments
Implemented Reverse Stock Split
"Our commitment remains steadfast in amplifying and emphasizing the benefits and practical applications of GIMOTI to reach as many patients as possible and grow revenues, thus doing well by doing good. We continue to receive inbound questions from physicians regarding diabetic gastroparesis and patients on GLP-1 analogs and have submitted two abstracts to ACG in response. We remain energized by the encouraging results generated to date and look forward to building on this momentum throughout the rest of the year,” Mr. D’Onofrio concluded.
Second Quarter 2024 Financial Review and Outlook
For the second quarter of 2024, net product sales were approximately $2.6 million compared to $1.1 million during the second quarter of 2023, and the net loss was approximately $1.3 million, or $0.93 per share compared with $1.9 million, or $6.70 per share, for the second quarter of 2023.
For the second quarter of 2024, selling, general and administrative expenses were approximately $3.7 million compared to $2.8 million for the second quarter of 2023. The increases were due to higher professional fees and reimbursement for expanded marketing efforts and profit-sharing activity with EVERSANA.
Total operating expenses for the second quarter of 2024 were approximately $3.8 million compared to $2.9 million for the same period in 2023.
As of June 30, 2024, cash and cash equivalents were approximately $9.2 million. We believe, based on our current operating plan, that our existing cash and cash equivalents, as well as future cash flows from net product sales of GIMOTI, will be sufficient to fund our operations into the second quarter of 2025.
Based on net sales generated in the first two quarters of 2024, Evoke is revising its 2024 guidance to a range of $11- 12
million from $14 million, still reflecting over a 100% increase from the previous year if achieved. Evoke’s 2024 guidance is dependent on its current business and expectations, including recent growth rates in net sales, assumptions regarding reimbursements and prescription fills, as well as factors that are outside of our control, such as the global macroeconomic and geopolitical environment, continued supply chain constraints and inflationary pressures.
About Evoke Pharma,Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.
Visit www.EvokePharma.com for more information.
Follow GIMOTI on Facebook
Follow Evoke Pharma on Facebook
Follow Evoke Pharma on LinkedIn
Follow Evoke Pharma on Twitter
About Gimoti® (metoclopramide) nasal spray
GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Important Safety Information
WARNING: TARDIVE DYSKINESIA
GIMOTI is not recommended for use in:
GIMOTI is contraindicated:
Potential adverse reactions associated with metoclopramide include: Tardive dyskinesia (TD), other extrapyramidal effects (EPS), parkinsonism symptoms, motor restlessness, neuroleptic malignant syndrome (NMS), depression, suicidal ideation and suicide, hypertension, fluid retention, hyperprolactinemia, effects on the ability to drive and operate machinery. Most common adverse reactions (≥5%) for GIMOTI are: dysgeusia, headache, and fatigue. These are not all of the possible side effects of GIMOTI. Call your doctor for medical advice about whether you should take GIMOTI and the possible risk factors and side effects. You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Safe Harbor Statement
Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,”“expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding: guidance regarding 2024 net product sales; potential future prescribing trends for GIMOTI based on Evoke’s or EVERSANA’s marketing efforts; Evoke’s commercialization plans, the potential market opportunity for GIMOTI, Evoke’s partnership with ASPN Pharmacies, growth in prescriptions, patients taking GIMOTI and the conversion of prescriptions to fills, and Evoke’s expected cash runway. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including, without limitation: Evoke may not be able to achieve its guidance for 2024 including as a result of decreased demand for GIMOTI; Evoke’s and EVERSANA’s ability to successfully drive market demand for GIMOTI; Evoke’s ability to obtain additional financing as needed to support its operations; Evoke may use its capital resources sooner than expected; warrant holders may choose not to exercise any of the outstanding warrants; Evoke’s dependence on third parties for the manufacture of GIMOTI; Evoke is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; Evoke’s ability to maintain intellectual property protection for GIMOTI; and other risks and uncertainties detailed in Evoke’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor & Media Contact:
Daniel Kontoh-Boateng
DKB Partners
Tel: 862-213-1398
dboateng@dkbpartners.net
Evoke Pharma, Inc.
Condensed Balance Sheets
|
|
June 30, 2024 |
|
|
December 31, 2023 |
|
||
|
|
(unaudited) |
|
|
|
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
9,177,836 |
|
|
$ |
4,739,426 |
|
Accounts receivable, net of allowance for credit losses of $0 |
|
|
2,003,003 |
|
|
|
673,071 |
|
Prepaid expenses |
|
|
382,936 |
|
|
|
885,040 |
|
Inventories |
|
|
544,765 |
|
|
|
481,840 |
|
Other current assets |
|
|
27,675 |
|
|
|
47,532 |
|
Total current assets |
|
|
12,136,215 |
|
|
|
6,826,909 |
|
Deferred offering costs |
|
|
— |
|
|
|
241,637 |
|
Total assets |
|
$ |
12,136,215 |
|
|
$ |
7,068,546 |
|
Liabilities and stockholders' equity (deficit) |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable and accrued expenses |
|
$ |
2,183,850 |
|
|
$ |
1,711,778 |
|
Accrued compensation |
|
|
425,797 |
|
|
|
1,324,010 |
|
Note payable |
|
|
5,000,000 |
|
|
|
5,000,000 |
|
Accrued interest payable |
|
|
1,861,610 |
|
|
|
1,612,295 |
|
Total current liabilities |
|
|
9,471,257 |
|
|
|
9,648,083 |
|
Total liabilities |
|
|
9,471,257 |
|
|
|
9,648,083 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholdersʼ equity (deficit): |
|
|
|
|
|
|
||
Preferred stock, $0.0001 par value; authorized shares — 5,000,000 |
|
|
— |
|
|
|
— |
|
Common stock, $0.0001 par value; authorized shares — 100,000,000 and |
|
|
73 |
|
|
|
28 |
|
Additional paid-in capital |
|
|
128,951,361 |
|
|
|
120,859,873 |
|
Accumulated deficit |
|
|
(126,286,476 |
) |
|
|
(123,439,438 |
) |
Total stockholdersʼ equity (deficit) |
|
|
2,664,958 |
|
|
|
(2,579,537 |
) |
Total liabilities and stockholders' equity (deficit) |
|
$ |
12,136,215 |
|
|
$ |
7,068,546 |
|
Evoke Pharma, Inc.
Condensed Statement of Operations
(unaudited)
|
|
Three Months Ended June 30, |
|
|||||
|
|
2024 |
|
|
2023 |
|
||
Net product sales |
|
$ |
2,551,366 |
|
|
$ |
1,131,368 |
|
Operating expenses: |
|
|
|
|
|
|
||
Cost of goods sold |
|
|
41,478 |
|
|
|
57,357 |
|
Research and development |
|
|
— |
|
|
|
92,357 |
|
Selling, general and administrative |
|
|
3,733,450 |
|
|
|
2,766,077 |
|
Total operating expenses |
|
|
3,774,928 |
|
|
|
2,915,791 |
|
Loss from operations |
|
|
(1,223,562 |
) |
|
|
(1,784,423 |
) |
Other income (expense): |
|
|
|
|
|
|
||
Interest income |
|
|
81,001 |
|
|
|
41,164 |
|
Interest expense |
|
|
(124,657 |
) |
|
|
(124,658 |
) |
Total other expense |
|
|
(43,656 |
) |
|
|
(83,494 |
) |
Net loss |
|
$ |
(1,267,218 |
) |
|
$ |
(1,867,917 |
) |
Net loss per share of common stock, basic and diluted |
|
$ |
(0.93 |
) |
|
$ |
(6.71 |
) |
Weighted-average shares used to compute basic and diluted |
|
|
1,363,525 |
|
|
|
278,558 |
|